|
Patent landscape, scope, and claims: |
Scope and Claims Analysis for US Patent 11,028,081 (Glaucoma/Ocular Hypertension Rho-Kinase Inhibitor Dosing Regimens)
US Patent 11,028,081 claims a method-of-treatment for glaucoma or ocular hypertension using a composition containing a Rho kinase inhibitor plus a pharmaceutically acceptable carrier, with broad coverage of dose range, administration route (including ocular), and dosing frequency (daily, weekly, monthly). The claim set is written to capture both immediate-use dosing regimens (once/twice/4 times per day) and prolonged dosing schedules (once/twice per week; once per month), while keeping the pharmacophore definition extremely wide through a generalized Rho-kinase-inhibitor structure with variable substituents (R1-R3, A, B, X1-X3, Z). Claim 1 is the backbone: all other claims narrow route (ocular) and operational details (dose mg/kg and dosing frequency).
What patents protect glaucoma or ocular hypertension using Rho kinase inhibitors with daily weekly monthly dosing?
Claim 1 scope: method of treatment + composition + dosing frequency
Independent claim 1 covers:
- Indication: treating glaucoma or ocular hypertension.
- Administration: administration of a composition comprising:
- a Rho kinase inhibitor, and
- a pharmaceutically acceptable carrier.
- Dosing frequency: administration is daily, weekly, or monthly.
- Rho kinase inhibitor form:
- Rho kinase inhibitor is a compound “is …” (the structural formula in the claim) or a pharmaceutically acceptable salt.
- Structural breadth:
- The Rho kinase inhibitor is defined by a Markush-style scaffold with:
- R1, R2, R3 each independently selected from a wide list including hydrogen, C1-C4 alkyl, aryl, alkyl-aryl, alkyl-heteroaryl, alkyl-heterocyclyl, C2-C4 alkenyl/alkynyl, carbonyl and related functionalities, alkoxy, sulfonyl and sulfonylamino, thioalkyl, carboxyl, or ring-forming options.
- A = C1-C4 alkyl, C1-C4 alkyl-aryl, C1-C4 alkyl-heteroaryl, or ring structure with R1/R2/R3.
- B = hydrogen, aryl/heteroaryl, cycloalkyl/heterocycloalkyl, or long-chain/sulfonyl/carbonyl/alkoxy/carboxyl options up to C1-C22.
- X1, X2, X3 independently from hydrogen, hydroxyl, halogen, C1-C4 alkyl, C2-C4 alkenyl/alkynyl, amino, aminocarbonyl, nitro, cyano, C1-C4 carbonyl and related, alkoxy, sulfonyl, sulfonylamino, thioalkyl, carboxyl.
- Double circle indicates aryl/heteroaryl.
- Each Z independently is a bond, C1-C4 alkyl, heteroalkyl, or O.
This is an unusually broad method claim because it treats the active ingredient identity as a large Markush family, while leaving the method operational parameters open (daily/weekly/monthly).
Claim 2-6: ocular route and dose and per-day subfrequencies
- Claim 2: method of claim 1 wherein administration is ocular administration.
- Claim 3: method of claim 1 wherein amount is about 0.001 to about 100 mg/kg (subject body weight).
- Claims 4-6: in daily dosing, frequency is:
- once daily,
- twice per day, or
- 4 times per day.
Claims 5 and 6 depend on claims that already include ocular (claim 2) or dose range (claim 3), respectively.
Claim 7-12: weekly dosing subfrequencies
- Claim 7-9: weekly administration is once weekly or twice weekly; with ocular and/or dose limitations applied in dependent claims.
- Claim 10-12: monthly administration is once a month, again with ocular route and/or dose range layered in dependent claims.
Claim 13-24: duplicate independent structure
Claims 13-24 repeat the same structure as claims 1-12, with the independent claim 13 mirroring claim 1. The presence of a second independent claim that “repeats” the operative structure suggests either:
- a second claim format to cover the same subject matter with a slightly different formal claim dependency or structural placement, or
- a drafting strategy to hedge against claim construction issues.
Functionally, the operative scope across both claim sets is the same: Rho kinase inhibitor composition + glaucoma/ocular hypertension + carrier + daily/weekly/monthly dosing with ocular route option + mg/kg dose range + frequency sub-options.
How broad are the Rho kinase inhibitor structural definitions (R1-R3, A, B, X1-X3, Z) in US 11,028,081?
Markush breadth drives the “active ingredient identity” coverage
The claim’s structural variables are not limited to small neighborhoods. They include:
- R1-R3: hydrogen and broad hydrocarbon/aromatic/heteroaromatic and carbonyl/sulfonyl/thio/carboxyl options, plus ring-forming behavior.
- B: hydrogen through C1-C22 substituents with multiple functional class options (alkyl, alkylaryl, alkylheteroaryl, alkenyl/alkynyl, carbonyl/carbonylamino, alkoxy, sulfonyl/sulfonylamino, thioalkyl, carboxyl).
- X1-X3: includes electron-withdrawing substituents (halogen, hydroxyl, nitro, cyano, carboxyl), heteroatoms, and multiple carbonyl-related classes.
Claim construction implications
Because claim 1 uses a general structural formula rather than a single named compound, an accused product could fall within the claims without requiring exact match to a particular Rho kinase inhibitor molecule, as long as the compound is within the defined substituent limits and satisfies the “Rho kinase inhibitor” role for glaucoma/ocular hypertension treatment.
What formulations are covered: solutions, suspensions, implants, or depot systems?
The claims require only:
- “a composition comprising a Rho kinase inhibitor” and
- “a pharmaceutically acceptable carrier,” and
- administration on daily/weekly/monthly schedules.
The claim language does not limit to a specific dosage form, excipient class, or release technology. As written, it can cover:
- topical ocular solutions and suspensions (carrier = aqueous/viscous vehicle),
- ophthalmic emulsions,
- in situ forming gels,
- ocular inserts (if “composition” and “carrier” are satisfied),
- depot-like approaches, provided the administration fits daily/weekly/monthly dosing.
Key point: the claims are method-of-treatment claims, not formulation product claims. Unless prosecution history limits “composition” or dosing schedule equivalents, product defense based on “dose form” alone may not avoid infringement if the administration schedule falls inside claim language.
When does US 11,028,081 lose exclusivity: expiration and patent term considerations?
No expiration date or priority information is provided in the prompt, so a precise term calculation cannot be produced here. What can be stated from claim content:
- The patent is a US method patent. Under US practice, exclusivity against generic entry typically hinges on the patent’s expiration and any regulatory exclusivity plus listing in the Orange Book for the relevant NDA/BLA.
- The method claims can also be asserted for “use-based” infringement, which can be relevant even when the generic drug product is sold but the generic label does not instruct the claimed regimen, depending on labeling and induced infringement standards.
A timeline with exact dates cannot be generated from the provided data.
What Orange Book status should be expected for a glaucoma ocular Rho-kinase inhibitor method patent?
The prompt provides claim text but not:
- the listed active ingredient(s),
- the NDA/BLA number,
- listed proprietary name(s),
- Orange Book patent/coverage type (drug product vs method-of-use).
So an Orange Book status determination cannot be produced from the given information.
How strong is the patent estate for glaucoma Rho-kinase inhibition around US 11,028,081?
Strength factors inside the claim
- Independent claim 1 is broad on dosing frequency: daily, weekly, or monthly.
- Broad active-ingredient family: Markush structure substantially increases probability of overlap with other members of the same scaffold family.
- Operational ranges:
- dose range is wide: 0.001 to 100 mg/kg.
- frequency includes common ophthalmic regimens (once, twice, qid; once/twice weekly; once monthly).
Strength constraints
- Method claims require a specific combination of:
- Rho kinase inhibitor composition,
- carrier,
- administration schedule matching the claim,
- and treatment of glaucoma/ocular hypertension.
- If a competitor uses a different mechanism (not a Rho kinase inhibitor) or uses a regimen outside the claimed frequency categories, it can avoid literal coverage. Under doctrine-of-equivalents, the “daily/weekly/monthly” and explicit subfrequency language can still narrow functional equivalents, though that is fact-dependent.
Without the rest of the estate (other US patents, continuations, international filings) and without knowing the actual Rho kinase inhibitor identity, no quantitative “estate strength score” can be computed.
How does US 11,028,081 compare to other glaucoma method patents targeting Rho kinase or related pathways?
Likely differentiation
This patent differentiates on two axes:
- Rho kinase inhibitor scaffold breadth: claim language defines a wide class of substituted structures.
- Dosing schedule breadth including monthly: many ocular glaucoma methods concentrate on daily dosing; the claim set explicitly includes weekly and monthly administration.
Other patents often focus narrowly on:
- a single compound,
- a specific formulation,
- or a specific dosing interval (e.g., once daily only).
US 11,028,081’s claim text is structured to cover longer-interval dosing approaches without limiting technology.
A cross-patent comparison needs actual competitor patents, which are not provided.
What generic entry risks exist for glaucoma Rho kinase inhibitor products if US 11,028,081 is listed?
Risk mechanism
If a competitor sells a product containing a claimed Rho kinase inhibitor and markets it for glaucoma/ocular hypertension in a regimen that matches:
- daily/weekly/monthly frequency, with
- ocular administration and dose within claimed mg/kg range,
then method-of-use infringement risk can arise even without product-by-product patent claims, depending on:
- whether the competitor’s label or marketing induces the claimed regimen,
- whether there is “skinny labeling,” and
- whether the method falls within the asserted claim set.
Key “design-around” levers
- Use a Rho kinase inhibitor outside the defined Markush structure.
- Change dosing frequency so it does not match claim categories (for example, non-integral schedules not captured by “once/twice per day,” “4 times per day,” “once/twice per week,” “once per month”).
- Use a route not covered if ocular is required (but note claim 1 itself does not require ocular; claim 2 does).
These are levers inferred from the claim text; specific entry scenarios require Orange Book and labeling details not supplied here.
What patent litigation affects US 11,028,081, including Paragraph IV or settlement terms?
No litigation captions, court venues, or settlement references are included in the prompt. A factual litigation landscape cannot be assembled from the provided information.
Key Takeaways
- US 11,028,081 claims a method of treating glaucoma or ocular hypertension using a Rho kinase inhibitor composition plus a pharmaceutically acceptable carrier.
- The claims are broad on dosing: daily, weekly, or monthly, with dependent claims specifying once/twice/4 times per day, once/twice per week, and once per month.
- Claim 1 covers a large family of Rho kinase inhibitor structures through Markush variables R1-R3, A, B, X1-X3, and Z, plus pharmaceutically acceptable salts.
- Dependent claims add practical operational limits: ocular administration and dose range of about 0.001 to about 100 mg/kg.
- Without the patent’s priority data, NDA/BLA linkage, or related patents/litigation records, an expiration date, Orange Book listing type, and estate-level strength assessment cannot be grounded in facts.
FAQs
-
Does US 11,028,081 require ocular administration to infringe?
No. Ocular administration is required only for dependent claims (e.g., claim 2). Claim 1 is not limited to ocular route.
-
Can a monthly dosing regimen avoid the patent by using a different release technology?
The claims do not limit formulation type, only administration schedule categories and composition elements.
-
How important is the mg/kg dose range to infringement risk?
The mg/kg limit appears in dependent claims (e.g., claim 3 and claim 15). Infringement of those dependents requires dosing within that range.
-
If a competitor uses a different Rho kinase inhibitor within the same general scaffold, is it covered?
The structural Markush language is designed to capture many substituted variants within the defined ranges, so scaffold-aligned analogs may fall within claim coverage.
-
What is the fastest way to assess generic litigation risk around this patent?
Identify whether the asserted Rho kinase inhibitor is the active ingredient in a relevant Orange Book listing and whether the generic label or induced use would match the claimed daily/weekly/monthly regimens.
References
- US Patent 11,028,081 (claim text provided in prompt).
More… ↓
⤷ Start Trial
|
